Article thumbnail
Location of Repository

Clinical management of Staphylococcus aureus bacteraemia

By Guy E. Thwaites, Jonathan D. Edgeworth, Effrossyni Gkrania-Klotsas, Andrew Kirby, Robert Tilley, M. Estee Toeroek, Sarah Walker, Heiman F. L. Wertheim, Peter Wilson, Martin J. Llewelyn and UK Clinical Infection Research Group

Abstract

Staphylococcus aureus bacteraemia is one of the most common serious bacterial infections worldwide. In the UK alone, around 12 500 cases each year are reported, with an associated mortality of about 30%, yet the evidence guiding optimum management is poor. To date, fewer than 1500 patients with S aureus bacteraemia have been recruited to 16 controlled trials of antimicrobial therapy. Consequently, clinical practice is driven by the results of observational studies and anecdote. Here, we propose and review ten unanswered clinical questions commonly posed by those managing S aureus bacteraemia. Our findings define the major areas of uncertainty in the management of S aureus bacteraemia and highlight just two key principles. First, all infective foci must be identified and removed as soon as possible. Second, long-term antimicrobial therapy is required for those with persistent bacteraemia or a deep, irremovable focus. Beyond this, the best drugs, dose, mode of delivery, and duration of therapy are uncertain, a situation compounded by emerging S aureus strains that are resistant to old and new antibiotics. We discuss the consequences on clinical practice, and how these findings define the agenda for future clinical research

Topics: RC0109
Publisher: Elsevier
Year: 2011
OAI identifier: oai:sro.sussex.ac.uk:7216
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dx.doi.org/10.1016/S147... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.